title: Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status.
abstract: BACKGROUND
  Poor performance status patients with advanced non-small cell lung cancer (NSCLC) have frequently been excluded from clinical trials due to the perception that they would have excessive treatment-related toxicity and a limited life expectancy.
  
  
  METHODS
  A retrospective review of two multicenter trials centered at the University of North Carolina of patients who were treated with platinum-based chemotherapy for advanced NSCLC was conducted. Patients were divided into two subgroups based on Karnofsky performance status (KPS). Patients with a KPS = 70 were considered to have poor performance status, while patients with a KPS > or =80 were considered to have good performance status.
  
  
  RESULTS
  Of the 387 patients, 19% (n = 73) had a poor performance status. The response rate (complete and partial responses) was similar between the two sub-groups (26% versus 28%); however, there was a difference in survival (p = 0.0004, log-rank test) between the groups. The median survival and 1-year survival rate for the poor performance status patients was 4.9 months and 21%, while the good performance status patients had a median survival of 8.4 months and a 1-year survival rate of 31%. The rate of National Cancer Institute (NCI) Common Toxicity Criteria (CTC) toxicities was similar between the two groups (p = 0.33). The percentage of patients receiving <4 cycles of therapy in the poor and good performance status was 55 and 39%, respectively (p = 0.012).
  
  
  CONCLUSIONS
  Patients with poor performance status treated with platinum based chemotherapy have a similar rate of toxicity compared to good performance status patients. Their overall survival was lower despite a similar response to chemotherapy.
authors.affiliation: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, 27599, USA. Thomas_Stinchcombe@med.unc.edu
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Stinchcombe
authors.forename: Jaeun
authors.initials: J
authors.lastname: Choi
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Schell
authors.forename: Andrea
authors.initials: A
authors.lastname: Mears
authors.forename: Paul E
authors.initials: PE
authors.lastname: Jones
authors.forename: Robert V
authors.initials: RV
authors.lastname: Nachtsheim
authors.forename: Mark A
authors.initials: MA
authors.lastname: Socinski
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000523:psychology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000523:psychology; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin